Short Interest in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Grows By 280.0%

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the recipient of a significant increase in short interest in March. As of March 31st, there was short interest totalling 22,800 shares, an increase of 280.0% from the March 15th total of 6,000 shares. Based on an average daily trading volume, of 1,030,000 shares, the days-to-cover ratio is currently 0.0 days. Approximately 4.1% of the company’s stock are sold short.

Bluejay Diagnostics Trading Down 2.8 %

Shares of BJDX stock traded down $0.07 during trading hours on Wednesday, hitting $2.27. 61,615 shares of the company were exchanged, compared to its average volume of 457,832. The company has a market capitalization of $1.25 million, a PE ratio of 0.00 and a beta of 0.35. Bluejay Diagnostics has a 52 week low of $2.17 and a 52 week high of $316.92. The business has a 50 day moving average of $3.70 and a two-hundred day moving average of $4.16.

Bluejay Diagnostics (NASDAQ:BJDX) last posted its quarterly earnings data on Monday, March 31st. The company reported ($112.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($36.00) by ($76.37).

About Bluejay Diagnostics

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.